At-home Leqembi, now sold as Leqembi Iqlik, is a subcutaneous autoinjector version of the Alzheimer's drug lecanemab that patients can inject themselves instead of visiting an infusion center. The FDA cleared it as a starting treatment on July 13, 2026, and Eisai and Biogen began selling it for new patients on August 24, 2026. For people newly diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's, the choice now is between a weekly injection done largely without clinic visits or the established biweekly IV infusion. Both deliver the same drug, but they differ in time commitment, monitoring structure, and how much is still unproven about real-world use outside a clinical trial.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resource:
- Read the original report from Beingpatient — Use this primary source to review the complete report.
Table of Contents
- What Changed With the July 2026 Approval
- How the Two Methods Compare Day to Day
- Safety Monitoring Still Follows the IV-Era Schedule
- What the Switch Costs, and What It Doesn't Solve
- Deciding Between the Two Options
- Frequently Asked Questions
What Changed With the July 2026 Approval
Before this decision, patients starting lecanemab had only one option: IV infusions at a clinic, administered on a schedule controlled by medical staff. The FDA's approval of Leqembi Iqlik for initiation-phase use let adults with mild cognitive impairment or mild Alzheimer's dementia begin treatment with self-administered injections instead, according to Biogen and Eisai's investor release. The regimen is specific: two 250 mg autoinjections, totaling 500 mg, given weekly for roughly the first 18 months of treatment, per Biogen's August 2026 release.
That matches the dosing intensity of the IV initiation phase, just delivered differently and on a different schedule. Notably, the FDA based this approval on pharmacokinetic bridging data, not a new efficacy trial. A CLARITY AD open-label-extension substudy showed that weekly subcutaneous dosing produces drug exposure similar to IV dosing, according to The Medical Letter. The agency treated matching drug levels in the blood as sufficient grounds for approval, rather than requiring a fresh study measuring cognitive outcomes with the injection form specifically.
How the Two Methods Compare Day to Day
The most visible difference is time. A subcutaneous dose takes about 15 seconds to inject, compared with roughly one hour for a clinic IV infusion visit, according to Pharmafocus Europe. That hour doesn't include travel, parking, or waiting room time, which is why injections are framed as the more convenient option. Convenience also shows up in a different burden: companionship.
About 80% of people receiving IV Leqembi need a caregiver or companion to accompany them to infusion-center visits, according to Being Patient. Proponents argue at-home injection can cut into that burden, but no study has directly measured whether it does. After initiation, patients move to a 360 mg weekly subcutaneous maintenance dose or continue biweekly IV infusions, and the companies state patients can switch between SC and IV administration throughout treatment, according to Precision Medicine Online. That flexibility means the choice isn't necessarily permanent.
- IV infusion: about one hour per visit, biweekly, administered by clinic staff, built-in supervision
- Subcutaneous injection: about 15 seconds per dose, weekly during initiation, self- or caregiver-administered at home
- Both: same drug (lecanemab), same underlying dosing intensity during the initiation phase
Safety Monitoring Still Follows the IV-Era Schedule
Lecanemab carries a risk of ARIA — brain swelling or bleeding detectable on MRI — and prescribing information requires monitoring scans before treatment and before specific doses, roughly one week prior to the 3rd, 5th, 7th and 14th doses, with management depending on ARIA type, severity and symptoms, according to Drugs.com's prescribing information summary. That schedule was built around IV dosing intervals. This matters for at-home injection because the monitoring structure hasn't been redesigned around a weekly self-administered regimen.
Patients still need to show up for MRIs at specified points even though they're no longer coming in for infusions, meaning the "no clinic visits" framing is not entirely accurate — it reduces infusion visits, not monitoring visits. Genotype testing adds another layer. FDA labeling recommends, but does not mandate, ApoE ε4 genotype testing before starting lecanemab, since ε4 homozygotes face higher ARIA risk, according to GenomeWeb's coverage of the labeling. A patient can start treatment — by injection or IV — without this test, but will then be starting without personalized risk information that testing would have provided.
What the Switch Costs, and What It Doesn't Solve
Leqembi Iqlik is priced at $385 per autoinjector, and the initiation regimen requires two devices per weekly dose, according to Managed Healthcare Executive. That's an added out-of-pocket and logistics factor that doesn't exist with infusion-center billing, where the clinic handles supply and administration as part of the visit. Self-administration at home also introduces an adherence question that supervised infusion doesn't have.
Clinicians and trade coverage note that home dosing carries a risk of missed or delayed doses without clinic oversight, and some patients resist switching from IV because of established relationships with infusion-center staff, according to Being Patient. For a population that includes people with mild cognitive impairment, missed doses from forgetting or difficulty with the injection process are a real possibility that infusion centers were designed to prevent. That's the central evidence gap: no study has measured how often doses get missed when patients or caregivers manage them at home, compared with the near-guaranteed administration of a scheduled clinic infusion. The approval established that the drug reaches comparable levels in the blood either way — it did not establish that adherence holds up the same way outside a clinic.
Deciding Between the Two Options
For a person newly diagnosed and starting treatment, the decision mostly comes down to logistics and support at home rather than drug effectiveness, since both delivery methods aim for the same drug exposure. Because patients can move between administration methods during treatment, starting with one option doesn't lock out the other. A caregiver struggling with the logistics of infusion visits can discuss switching to injections, and someone finding self-injection or adherence difficult at home can move back to supervised IV administration.
- Choose IV infusion if: consistent administration matters more than convenience, a caregiver already manages infusion-center visits reliably, or there's discomfort with self-injection
- Choose at-home injection if: travel time or caregiver availability for hour-long clinic visits is the bigger obstacle, and there's a reliable system in place for remembering weekly doses and keeping MRI monitoring appointments
- Either way: ARIA monitoring MRIs still need to happen on schedule, and switching between SC and IV later is possible if the first choice isn't working
Frequently Asked Questions
Does the at-home injection work as well as the IV infusion?
The approval rests on pharmacokinetic bridging data showing weekly subcutaneous dosing produces drug exposure similar to IV dosing, not a separate efficacy trial, according to The Medical Letter.
Can a patient switch between IV and at-home injection later?
Yes. After the initiation phase, patients can continue biweekly IV infusions or move to weekly subcutaneous maintenance dosing, and the companies state switching between the two is possible throughout treatment, according to Precision Medicine Online.
Does at-home injection eliminate clinic visits entirely?
No. ARIA monitoring still requires MRIs before treatment and before specific doses on a schedule set out in prescribing information, according to Drugs.com.
You Might Also Like
- High Cholesterol in the 2026 WHO Dementia Guideline: What the Evidence Supports and Does Not Promise for Adults in Midlife
- Diabetes in the 2026 WHO Dementia Guideline: What the Evidence Supports and Does Not Promise for Adults in Midlife
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
